Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Model-Based Evaluation of the Warfarin-Sulfamethoxazole Drug-Drug Interaction.

Created on 13 Oct 2026

Authors

Koki Takeda, Toshinori Hirai, Kokoha Okamoto, Ayu Sugioka, Akira Okada, Nobuhito Shibata

Published in

European journal of drug metabolism and pharmacokinetics. Oct 12, 2026. Epub Oct 12, 2026.

Abstract

Warfarin exhibits complex drug-drug interactions (DDIs), particularly with sulfamethoxazole, which competitively inhibits cytochrome P450 2C-mediated metabolism of S-warfarin. This study developed a population pharmacokinetic-pharmacodynamic (PK-PD) model to evaluate the DDI of warfarin with different doses of sulfamethoxazole/trimethoprim using a model-based approach.
Male Wistar rats (n = 4 per group) received intravenous warfarin (400 μg/kg) with or without therapeutic or standard prophylactic doses of sulfamethoxazole/trimethoprim (200/40 mg/kg and 100/20 mg/kg, respectively). Plasma concentrations of S-warfarin and sulfamethoxazole and the prothrombin time international normalized ratio (PT-INR) were recorded. After developing a population PK-PD model of the interaction between S-warfarin and sulfamethoxazole, simulations were conducted with a target trough PT-INR of 2.0 at steady state. The required warfarin dose was compared between the WF alone, WF+TD-ST (ST 200/40 mg/kg), WF+SPD-ST (ST 100/20 mg/kg), and WF+LPD-ST (ST 20/4 mg/kg) groups.
Among the groups, the WF+TD-ST group exhibited the highest S-warfarin AUC0-∞ (77.6 ± 9.3 μg × h/mL) and peak PT-INR (2.5 ± 0.6), indicating the greatest increase in both warfarin exposure and anticoagulant effect. Population PK-PD model simulations indicated that warfarin dose reductions of approximately 45%, 75%, and 85% were required as the sulfamethoxazole dose increased to maintain a target trough PT-INR of 2.0 at steady state. Our population PK-PD model quantified the warfarin-sulfamethoxazole DDI.
The proposed model supports model-based warfarin dosing during co-administration with different doses of sulfamethoxazole/trimethoprim.

PMID:
42862535
Bibliographic data and abstract were imported from PubMed on 13 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 16
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement